Remdesivir Drug Asset Due Diligence Report 2026

This Remdesivir Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

113

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Remdesivir can convert its Small molecule drug profile and RdRp biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Remdesivir (query alias: remdesivir)
Modality / target	Small molecule drug; RdRp; RdRp inhibitors
Highest global status	Approved
Originator	Gilead Sciences, Inc.
Active developers	Gilead Sciences Canada, Inc., Gilead Sciences Ireland UC, Gilead Sciences, Inc.

The MCP disease footprint includes COVID-19, Autoimmune Diseases, Hematologic Neoplasms. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07013474	Phase 3	Recruiting	300	The difference in the proportion of patients meeting the primary composite endpoint, between ibuzatrelvir and remdesivir vs remdesivir groups in symptomatic adult participants with COVID-19 who are severely immunocompromised
NCT06873633	Phase 2	Recruiting	120	Safety and tolerability of Remdesivir
NCT06817889	Phase 2	Recruiting	60	Proportion of participants requiring ≥ 2 liters/minute of oxygen for ≥ 24 consecutive hours

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

An open-label, clinical feasibility study of the efficacy of Remdesivir for Long-COVID

Phase 2; n=72; evaluation: Positive. Reported fields: EQ-5D-5L = 7.0 point

A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With Acute Respiratory Distress Syndrome Associated With COVID-19 (Trial H2: Remdesivir)

Phase 3; n=87; evaluation: not stated. Reported fields: Number of Participants With a 6-category Primary Ordinal Outcome (Recovery) at Day 90: Odds Ratio (OR) = 0.98(95% CI, 0.45 - 2.11), P-Value = 0.96; Number of Participants With a 6-category Primary Ordinal Outcome (Recovery) at Day 90: Odds Ratio (OR) = 0.98(95% CI, 0.45 - 2.11), P-Value = 0.96; Number of Participants With a 6-category Primary Ordinal Outcome (Recovery) at Day 90: Odds Ratio (OR) = 0.98(95% CI, 0.45 - 2.11), P-Value = 0.96

A Dose Finding Human Experimental Infection Study in Healthy Subjects Using a GMP-produced SARS-COV-2 Wild Type Strain

Not Applicable; n=36; evaluation: not stated. Reported fields: Number of Unsolicited Adverse Events in Healthy Participants Challenged With Wild Type SARS-CoV-2 = 45 Unsolicited Adverse Events ; -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Remdesivir addresses COVID-19, Autoimmune Diseases, Hematologic Neoplasms. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 9 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-02-07	University of Pennsylvania and University of Maryland collaborate on a study of combining remdesivir or molnupiravir with brequinar for COVID-19.	Phase 2	Financial terms not disclosed
2020-12-07	Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology	Approved	Financial terms not disclosed
2020-06-13	Dr. Reddy's Laboratories Enters Into Licensing Agreement With Gilead Sciences For Remdesivir	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Remdesivir cocrystal, compositions and methods thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO